GHP Investment Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$231K Sell
4,826
-35
-0.7% -$1.5K 0.01% 385
2026
Q1
$179K Sell
4,861
-1,985
-29% -$94.1K 0.01% 401
2025
Q4
$348K Buy
6,846
+2,075
+43% +$106K 0.01% 341
2025
Q3
$265K Hold
4,771
0.01% 353
2025
Q2
$329K Hold
4,771
0.01% 335
2025
Q1
$331K Buy
4,771
+33
+0.7% +$2.73K 0.02% 331
2024
Q4
$408K Buy
4,738
+178
+4% +$19.2K 0.02% 310
2024
Q3
$543K Sell
4,560
-134
-3% -$17.9K 0.02% 300
2024
Q2
$670K Buy
4,694
+134
+3% +$17.8K 0.03% 283
2024
Q1
$586K Hold
4,560
0.03% 297
2023
Q4
$472K Hold
4,560
0.03% 310
2023
Q3
$466K Hold
4,560
0.03% 306
2023
Q2
$414K Hold
4,560
0.02% 319
2023
Q1
$363K Sell
4,560
-110
-2% -$7.8K 0.02% 320
2022
Q4
$316K Hold
4,670
0.02% 330
2022
Q3
$233K Buy
4,670
+110
+2% +$5.89K 0.02% 337
2022
Q2
$254K Sell
4,560
-194
-4% -$10.8K 0.02% 330
2022
Q1
$264K Buy
4,754
+194
+4% +$9.96K 0.02% 330
2021
Q4
$255K Hold
4,560
0.02% 296
2021
Q3
$219K Buy
+4,560
New +$220K 0.02% 291

Other funds holding NVO

GHP Investment Advisors's NVO Position: Q2 2026 in Review

GHP Investment Advisors reduced its Novo Nordisk (NVO) stake by 0.72% in Q2 2026, selling an estimated $1.5K and leaving 4,826 shares worth $231K. The position accounts for 0.01% of the portfolio, ranked #385.

GHP Investment Advisors first reported a position in NVO in Q3 2021 and has held it in 20 quarters since. The position peaked at $670K in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • GHP Investment Advisors held 4,826 shares of Novo Nordisk worth $231K as of Q2 2026.
  • GHP Investment Advisors sold 35 Novo Nordisk shares in Q2 2026, an estimated $1.5K.
  • Novo Nordisk made up 0.01% of GHP Investment Advisors's portfolio in Q2 2026, its #385 holding.
  • GHP Investment Advisors first reported a position in Novo Nordisk in Q3 2021 and has held it in 20 quarters since.
  • GHP Investment Advisors's Novo Nordisk position peaked at $670K in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on GHP Investment Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.